We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bristol-Myers Squibb has been left somewhat red-faced after its combination of Opdivo and Yervoy failed to show any statistically significant benefits in progression-free survival versus Pfizer’s Sutent in the ...